Alberto Cipriani
@albcipri6
Followers
319
Following
1K
Media
7
Statuses
238
Cardiologist. Researcher @UniPD. Cardiomyopathies and CMR are my field of interest.
Veneto, Italy
Joined August 2019
🚨🇮🇹New multicenter Italian study on early-stage ATTRwt-CM treated with tafamidis: clinical & biochemical markers help identify high-risk cases🫀 📣out in JACC: HF https://t.co/JJdW7LnOyW
@albcipri6
@amyloid_papers
@UniPadova
0
3
7
High-Sensitivity Cardiac Troponin I for Risk Stratification in Wild-Type Transthyretin Amyloid Cardiomyopathy @matser89 @aldoporcari @TiniGiacomo @GSaturi @LauraDemichieli @albcipri6 #AHAJournals
https://t.co/m4vcT1aFyM
0
16
40
High-Sensitivity Cardiac Troponin I for Risk Stratification in Wild-Type Transthyretin Amyloid Cardiomyopathy @matser89 @aldoporcari @TiniGiacomo @GSaturi @LauraDemichieli @albcipri6 #AHAJournals
https://t.co/m4vcT1aFyM
0
2
2
Gli esperti portano l’esperienza sul tema dell’amiloidosi cardiaca. Se non curata, questa malattia può essere mortale, anche in breve tempo. I clinici ammettono che siamo di fronte a prospettive radiose di futuro in termini di innovazione terapeutica sulla quale serve investire
0
1
2
📢#RCM-Vol. 25 No. 9 📚Title "The 2023 European Task Force Criteria for Diagnosis of Arrhythmogenic Cardiomyopathy" 🤵Authors: Graziano et al. @AlessandroZor14 @lungaro13 @BauceBarbara @albcipri6 @Proteom @Cristinabasso64 @DCorradoCardio
https://t.co/nRnPigTStQ
#CardioEd
imrpress.com
Arrhythmogenic cardiomyopathy (ACM) is a cardiac disease featured by non-ischemic myocardial scarring linked to ventricular electrical instability. As there is no single gold-standard test, diagnos...
1
3
5
I risultati dello studio HELIOS-B, presentati a #ESCCongress e pubblicati sul @NEJM, hanno messo in evidenza l’efficacia di vutrisiran nel trattamento dell'ATTR-CM. Abbiamo chiesto un commento ad @albcipri6. https://t.co/aEUfcsHiTa
cardioinfo.it
Lo studio HELIOS-B ha messo in evidenza l’efficacia di vutrisiran nel trattamento dei pazienti con amiloidosi cardiaca da transtiretina.
0
1
5
An ECG that changed life to the Brugada Brothers, but also to somebody else. https://t.co/OmSNxyEYnt
heartrhythmjournal.com
I highly appreciate Pedro and Josep Brugada for their beautiful tale of the origin of the syndrome1 and especially for their fair admission that the Padova cardiologists (led by the great yet...
0
3
6
@IJCVImaging @domcbenz @RaberLorenz @ARrosendael @isaacshiri @MarcoGuglielmo @EdoardoConte16 🔍 I selected ✋🏻 must-read articles from April's #IJCVI, showcasing #YesCCT's crucial role in #TAVI aortic stenosis management. 💡Photon counting #PCCT innovation: 🚀boosts diagnostic precision & improves risk stratification in valve disease! @IntJCVImaging @ShehabAnwer
1
5
11
🚀 Do u know what Radiomics is? ‼️Texture analysis to extract and quantify patterns not straight forwardly detectable by human eye 🧲identify patients with AMI on #whyCMR bSSFP images! 👉 will LGE be useless in the future?🤨 👁️: https://t.co/ix6WeKoQJG
@IJCVImaging @SCMRorg
3
13
27
#whyCMR in the assessment of the anomalous RCA originating from the left sinus of Valsalva. Read on EHJ our last contribution with @DCorradoCardio @Cristinabasso64 @MauroLoRito @SCMRorg
academic.oup.com
Risk stratification and therapeutic management of patients with an anomalous right coronary artery originating from the left sinus of Valsalva (R-ACAOS) re
0
1
8
The #IJCVI editors' aim is stellar! Let's meet them & know their aim in this video🌠 @SheilaHegde @h_hellmut @BFoldyna @RKwongMD @ARrosendael @MarcoGuglielmo @albcipri6 @domcbenz @RaberLorenz @AnnaGiuliaPavon @isaacshiri @shehabanwer @chrisgraeni @JGrapsa @hragy #CardioTwitter
0
7
10
Dr. @LauraDemichieli, et al discuss the significant aspects of cTn biology & measurement methods, potential mechanisms of myocardial injury in CA, & the clinical application of cTn in the mgmt of both AL & #ATTR #amyloidosis. https://t.co/PupQd6d4z3
#JACCCardioOnc @albcipri6
0
6
27
🚨Don't miss this @JACC #JACCCardioOnc State-of-the-Art Review about #cTn in patients with light chain and transthyretin #CA! #HeartMonth #CardioOnc 📰 https://t.co/zOCTEqhTLn
0
26
57
🔴 Phenotypic Expression & Clinical Outcomes in Patients With Arrhythmogenic Cardiomyopathies @JACCJournals #CardioEd #Cardiology
1
15
46
🚨🚨New insights on amyloidosis epidemiology in Northeast Italy 🫀Check out our new manuscript @albcipri6 @UniPadova “Hospitalization-based epidemiology of systemic and cardiac amyloidosis in the Veneto Region, Italy” - International Journal of Cardiology
internationaljournalofcardiology.com
Defining the epidemiology of systemic and cardiac amyloidosis (CA) is a contemporary challenge. The present study aimed to estimate incidence and time trends in amyloidosis-related hospitalizations...
1
3
13
This week, we’re highlighting JAHA's Top Ten Research Impact Articles of 2023. Congratulations to the authors of our Top Ten, and thank you for your contributions to JAHA! See our Editor’s Note for details about our selection process: https://t.co/X0Os1hOpqq
1
3
8
LA strain reservoir and LA contractile strain predict thromboembolic events in amyloid cardiomyopathy, independent of AF ‼️75% of TEs occurred without prior documentation of atrial fibrillation https://t.co/jtbGf5Fdlk
0
4
25
Cosa ne pensi dell'attuale impiego clinico della Risonanza Magnetica Cardiaca nella Tua esperienza lavorativa? 🧲♥️ Soddisfacente? Utile? 😃 Perfettibile? Inadeguato? 🤨 Inutile? Dannoso? 😒 5 minuti di Survey per dire la Tua 🔜🎙️ Link di seguito⤵️ https://t.co/a20b43x0KV
0
10
14
(1/11) The @US_FDA has denied the sNDA for #patisiran for an indication for #ATTR-CM, based on the APOLLO-B trial. 😮One can respect the process but disagree with the result -- and I think this was a major miss by @US_FDA. A brief🧵... #amyloidosis
businesswire.com
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has iss...
7
39
102